Agilent Technologies Inc. (NYSE: A) today announced an agreement for
global distribution of Cartagenia’s cloud-based software for copy number
variation (CNV) analysis. This agreement will enable Agilent to sell
usage-priced annual licenses for Cartagenia’s Bench Lab CNV module to
small and medium-sized cytogenetic laboratories. The use-based licenses
allow labs with limited budgets and little or no bioinformatics
resources to gain access to a powerful interpretation support module to
draft clinical grade reports.
“Cartagenia is pleased to work with Agilent on this distribution
agreement of our Bench Lab CNV module,” said Herman Verrelst, chief
executive officer, Cartagenia. “Patient-centric interpretation of
microarray data can be greatly facilitated by adopting automated data
analysis pipelines and workflows, increasing lab efficiency.”
“With expanded distribution capabilities, we can now reach small- to
medium-sized labs more efficiently and provide them with our data
analysis platform,” Verrelst added. “The CNV module is a proven
platform, offers standardized workflows, and automated SOPs for fast
turnaround times. Since it is a cloud-based platform, it allows for
rapid installation, integration with legacy data, and provides labs with
greater access to our product without adding bioinformatics resources.”
Cartagenia supplies interpretation support software, database systems
and related services to genetic labs and clinicians, enabling them to
perform clinically relevant analysis of genetic findings quickly and
efficiently.
The Cartagenia Bench CNV platform is built in collaboration with
genetics labs and clinical experts involved in routine medical practice.
Because of this, Bench Lab CNV addresses the specific needs of genetic
diagnostic labs and clinicians.
“Agilent is the first worldwide reseller to offer the Cartagenia Bench
Lab CNV, and we are excited to provide this solution,” said Jacob
Thaysen, Agilent’s vice president and general manager, Diagnostics and
Genomics Group. “Labs with minimal software budget and resources can now
afford to implement proven, standardized processes to analyze,
interpret, and report their CGH data and generate precise draft lab
reports with minimal disruption to their analysis workflow and staff.”
To learn more, please visit www.agilent.com/genomics/cartagenia.
About Cartagenia
Cartagenia Bench Lab CNV is built using a certified ISO13485 Quality
Management System and is registered with the FDA as an exempt Class I
Medical Device in the United States and as a Class I Medical Device in
Europe in conformity with the essential requirements and provisions of
the Council Directive 93/42/EEC concerning medical devices, and with the
relevant harmonized standards EN ISO62304. www.cartagenia.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement
company and a technology leader in chemical analysis, life sciences,
diagnostics, electronics and communications. The company’s 20,600
employees serve customers in more than 100 countries. Agilent had
revenues of $6.8 billion in fiscal 2013. Information about Agilent is
available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly
traded companies through a tax-free spinoff of its electronic
measurement business. The new company is named Keysight Technologies,
Inc. The separation is expected to be completed in early November 2014.
Agilent Cytogenomics software is For Research Use Only. Not for use in
diagnostic procedures.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
Copyright Business Wire 2014